dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
Published 4 years ago • 124 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
1:46
dr. wakelee on single-agent immunotherapy in nsclc
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc
-
2:21
dr. wakelee on the rationale for immunotherapy in nsclc
-
9:41
immunotherapy with antiangiogenics in nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:20
novel immunotherapy combinations for nsclc
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
3:05
rationale behind antiangiogenic therapy in nsclc
-
1:04
dr. wakelee on the avaperl trial
-
1:21
dr. wakelee on importance of ngs testing in nsclc
-
1:40
dr. wakelee on immediate therapy options in lung cancer
-
2:13
dr. malhotra on pembrolizumab during concurrent chemoradiation in nsclc
-
2:19
dr. otterson on when to start immunotherapy in nsclc
-
1:10
dr. patel on immunotherapy landscape of stage iv nsclc
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
2:20
dr. kris on the relay trial in egfr nsclc